Scholar Rock Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 30, 2020, regarding events occurring on October 27 and 28, 2020. Scholar Rock Holding Corp., a biopharmaceutical company, announced a public offering of common stock and pre-funded warrants to raise capital.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 2,948,718 shares of Common Stock and 2,179,487 Pre-Funded Warrants.
- Option Shares: Underwriters granted a 30-day option to purchase up to 769,230 additional shares.
- Offering Price: $39.00 per share for Common Stock; $38.9999 per Pre-Funded Warrant.
- Estimated Net Proceeds: Approximately $187.6 million (base case) or $215.8 million (if option fully exercised), after deducting underwriting discounts and estimated expenses.
- Closing Date: Expected on or about November 2, 2020.
Material Changes and Agreements
The Company entered into a Material Definitive Agreement (Underwriting Agreement) with J.P. Morgan Securities LLC, Jefferies LLC, and Credit Suisse Securities (USA) LLC. Concurrently, the Company terminated a prior Open Market Sale Agreement with Jefferies LLC. No shares had been sold under the terminated agreement, and no early termination penalties were incurred.
Outlook, Risks, and Unusual Items
The offering is being made pursuant to a shelf registration statement on Form S-3. The Pre-Funded Warrants are exercisable immediately but are subject to beneficial ownership limitations (9.99% cap, extendable to 19.99% with notice). The filing does not provide specific operational guidance or risk factors beyond standard underwriting terms and customary representations.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received.
- Confirm whether the underwriters exercised the option to purchase the 769,230 additional shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification and market standoff provisions.
- Monitor the Company's cash position post-closing to assess runway for clinical development.